Press Releases

Date Headline
9/26/2022
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
 Summary
Institutional Shareholder Services joins Glass Lewis in recommending a vote FOR the Redomicile resolution ISS cites potential for improved capital raising ability and commercialization efficiencies for the Company's lead product candidate, zanidatamab To vote, contact Kingsdale Advisors at  Continue Reading
9/16/2022
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
 Summary
Independent proxy advisory firm Glass Lewis recommends that   Zymeworks shareholders vote FOR the Redomicile resolution Glass Lewis notes Zymeworks has made a compelling case that the Redomicile will favor the Company on the basis of more favorable corporate law To vote, contact Kingsdale Advisors  Continue Reading
9/12/2022
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
 Summary
Company to hold conference call and webcast on Monday, September 12 th at 4:30 PM Eastern Standard Time (EST) VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Sep. 12, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,  Continue Reading
9/8/2022
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
 Summary
Redomicile anticipated to enhance long-term value for securityholders,   provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growth Zymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile resolution To vote,  Continue Reading
9/4/2022
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
 Summary
Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers Results to be reviewed in an oral presentation at European Society for Medical Oncology (ESMO) Congress 2022 in Paris Monday , September 12 at 5:25 pm  Continue Reading
8/4/2022
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
 Summary
Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September Announced Early Research and Development (eR&D) day presentation and webcast for October 20 th , 2022 with focus on TOPO1i antibody-drug  Continue Reading
8/1/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Aug. 1, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: Citi’s 17  Continue Reading
7/25/2022
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
 Summary
Oral presentation will take place on Monday, September 12 at 5:25 pm Central European Summer Time (CEST) VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 25, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today  Continue Reading
7/22/2022
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 22, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE  Continue Reading
7/21/2022
Zymeworks to Host Second Quarter Results Conference Call
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Jul. 21, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on  Continue Reading
Displaying 1 - 10 of 34
Copyright 2022 , Zymeworks Inc.